Intranasal steroids in treatment of allergic rhinitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Allergic rhinitis (AR) is one of the most common diseases affecting adults and children. AR is often a part of a systemic inflammatory process associated with other inflammatory conditions, including allergic conjunctivitis (Ac), rhinosinusitis and asthma. Undertreated AR impairs quality of life, exacerbates asthma and is a major factor in asthma development. There is a strong recommendation that clinicians recommend intranasal steroids (INS) for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. All modern INS are minimally bioavailable and similar with regard to efficacy and safety at the recommended starting dose. however, differences in patient preference and safety of use during pregnancy may contribute to primary care physicians’ selection of an INS therapy for their patients.

Full Text

Restricted Access

About the authors

O M Kurbacheva

Institute of Immunology

Moscow, Russia

S M Shwets

Institute of Immunology

Email: smshvets@gmail.com
Moscow, Russia

References

  1. Bousquet J., Khaltaev N., Cruz A. et al. ARIA Update. Allergy. 2008, v. 63, 160 р.
  2. Szeinbach S.L., Seoane-Vazquez E.C., Beyer A., Williams P.B. The impact of allergic rhinitis on work productivity. Prim. Care Respir. 2007, v. 16, p. 98-105.
  3. Meltzer E.O. Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. 2001, v. 108, p. 45-53.
  4. Beggs PJ. Impacts of climate change on aeroallergens: past and future. Clin. Exp. Allergy. 2004, v. 34, p. 1507-1513.
  5. Rogers C.A., Wayne P.M., Macklin E.A et al. Interaction of the onset of spring and elevated atmospheric CO2 on ragweed (Ambrosia artemisiifolia L.) pollen production. Environ Health Perspect. 2006, v. 114, p. 865-869.
  6. Burbach G.J., Heinzerling L.M., Edenharter G. et al. GA2LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009, v. 64, p. 1507-1515.
  7. Bertelsen R.J., Carlsen K.C., Carlsen K.H. Rhinitis in children: co-morbidities and phenotypes. Pediatr. Allergy Immunol. 2010, v. 21, p. 612.
  8. Chawes B.L., Bonnelykke K., Kreiner-Moller E. et al. Children with allergic and nonallergic rhinitis have a similar risk of asthma. Allergy Clin. Immunol. 2010, v. 126, p. 567-573.
  9. Ponte E.V., Franco R., Nascimento H.F. et al. Lack of control of severe asthma is associated with co-existence of moderate -to-severe rhinitis. Allergy. 2008, v. 63, p. 564-569.
  10. Masuda S., Fujisawa T., Katsumata H. et al. High prevalence and young onset of allergic rhinitis in children with bronchial asthma. Pediatr Allergy Immunol. 2008, v. 19, p. 517-522.
  11. De Groot E.P., Nijkamp A., Duiverman E.J. et al. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax. 2012, v. 67, p. 582-587.
  12. Lasmar L.M., Camargos P. A., Ordones A. et al. Prevalence of allergic rhinitis and its impact on the use of emergency care services in a group of children and adolescents with moderate to severe persistent asthma. Pediatr. 2007, v. 83, p. 555-561.
  13. Canonica G.W., Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin. Exp. Immunol. 2009, v. 158, p. 260-271.
  14. Cirillo I., Marseglia G., Klersy C. et al. Allergic patients have more numerous and prolonged respiratory infections than non-allergic subjects. Allergy. 2007, v. 62, p. 1087-1090.
  15. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт Медиа». 1998, 248 с.
  16. Гущин И.С., Курбачева О.М. Аллергия и аллергенспеци-фическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, 227 с.
  17. Mori L., Kleimberg J., Mancini C. et al. Bronchial epithelial cells of atopic pacients with asthma lack the ability to inactivate allergens. Biochem. Biophys. Res. Commun. 1995, v 217, p. 817-822.
  18. Rapiejko P., Stankiewicz W., Szczygielski K. et.al. Threshold pollen count necessary to evoke allergic symtoms. Otolaringol. Pol. 2007, v. 61, p. 591-594.
  19. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1-receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998, v. 317, p. 1624-1629.
  20. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1-receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann. Allergy Asthma Immunol. 2002, v. 89, p. 479-484.
  21. Weinstein S.F. Combination therapy in the treatment of allergic rhinitis. Allergy Asthma Proc. 2002, v. 23, p. 1-3.
  22. российский Аллергологический ^Журнал № 6-2015 Интраназальные кортикостероиды в лечении аллергического ринита
  23. Skoner D., Rachelefsky G., Meltzer E. et al. Detection of growth suppression in children during treatment with intranasal belcomethasone dipropionate. Pediatrics. 2000, v. 105, p. 23.
  24. Allen D.B., Meltzer E.O., Lemanske R.F. et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002, v. 23, p. 407-413.
  25. Schenkel E.J., Skoner D.P., Bronsky E.A. et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000, v. 105, p. 22.
  26. Lee L., Sterling R., Maspero J. et al. Growth velocity reduced with once-daily Fluticasone furoate nasal spray in prepubes-cent children with perennial allergic rhinitis. JACI Pract. 2014, v. 2, p. 421-427.
  27. Kim K.T., Rabinovitch N., Uryniak T. et al. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann. Allergy Asthma Immunol. 2004, v. 93, p. 61-67.
  28. Muller C., Ahlstrom H., Henricson K.A. et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clinical & Experimental Allergy. 2003, v. 6, p. 816-822.
  29. Glenis K. Scadding. Optimal Management of Allergic Rhinitis. Arch. Dis. Child. 2015, v. 100, p. 576-582.
  30. Marple B.F., Fornadley J.A., Patel A.A. et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol. Head Neck Surg. 2007, v. 136, p. 107-124.
  31. Keith P.K., Desrosiers M., Laister T. et al. The burden of allergic rhinitis in Canada: perspectives of physician and patients. Allergy Asthma Clin. Immunol. 2012, v. 1, p. 8.
  32. Baena-Cagnani C.E. Safety and tolerability of treatments for allergic rhinitis in children. Drug. Saf. 2004, v. 27, p. 883-898.
  33. Lindqvist N., Balle V.H., Karma P. et al. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study. Allergy. 1986, v. 41, p. 179-186.
  34. Pipkorn U., Pukander J., Suonpaa J. et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin. Allergy. 1988, v. 18, p. 253-259.
  35. Norjavaara E., de Verdier M.G. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J. Allergy Clin. Immunol. 2003, v. 111, p. 736-742.
  36. Kallen B., Rydhstroem H., Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet. Gynecol. 1999, v. 93, p. 392-395.
  37. U.S. Food and Drug Administration. U.S. FDA labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed. Regist. 1979, v. 44, p. 37434-37467.
  38. Yawn B. Comparison of once-daily intranasal corticosteroids for the treatment of allergic rhinitis: are they all the same? Med. Gen. Med. 2006, v. 25, p. 23.
  39. Курбачева О.М., Польнер С.А., Смирнов Д.С. Аллергический ринит. Вечная проблема и ее современное решение. Медицинский совет. Оториноларингология. 2015, № 5, c. 84-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2015



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies